Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
$3M-57.1%$7M$0-100%$677K-91.2%$7.68M
$70.56M+27.3%$55.42M-18.8%$68.26M+6.8%$63.9M-13.4%$73.81M+8.4%
$11.03M-9.7%$12.22M+0.7%$12.13M-11.0%$13.63M-27.3%$18.74M+10.9%
$81.59M+20.6%$67.63M-15.9%$80.39M+3.7%$77.52M-16.2%$92.55M+8.9%
$81.59M+20.6%$67.63M-15.9%$80.39M+3.7%$77.52M-16.2%$92.55M+8.9%
-$78.59M-29.6%-$60.63M+24.6%-$80.39M-4.6%-$76.85M+9.5%-$84.87M+0.1%
-2,619.7%-1,754pp-866.1%-11,351.1%-10,246pp-1,105.2%
$5.35M-6.3%$5.71M-10.9%$6.41M-9.8%$7.11M-9.1%$7.81M-12.9%
$5.3M-7.7%$5.74M-8.0%$6.24M-3.6%$6.47M-17.1%$7.8M-13.0%
-$73.29M-33.5%-$54.89M+26.0%-$74.15M-5.4%-$70.38M+8.7%-$77.07M-1.4%
-2,443%-1,659pp-784.1%-10,395.1%-9,392pp-1,003.6%
-$0.41-32.3%-$0.31+27.9%-$0.43-4.9%-$0.41+10.9%-$0.46-9.5%
-$0.41-32.3%-$0.31+27.9%-$0.43-4.9%-$0.41+10.9%-$0.46-9.5%
179.8M+4.8%171.6M-0.5%172.4M+0.7%171.3M+1.2%169.2M+18.5%
$53K$9K
-$73.46M-34.4%-$54.65M+25.6%-$73.49M-4.1%-$70.58M+7.2%-$76.04M+4.4%
$5.35M-6.3%$5.71M-10.9%$6.41M-9.8%$7.11M-9.1%$7.81M-12.9%
-$172K-172%$240K-63.4%$656K+426%-$201K-120%$1.03M+129%
-$172K-172%$240K-63.4%$656K+426%-$201K-120%$1.03M+129%
$5.3M-7.7%$5.74M-8.0%$6.24M-3.6%$6.47M-17.1%$7.8M-13.0%
$70.56M+27.3%$55.42M-18.8%$68.26M+6.8%$63.9M-13.4%$73.81M+8.4%
$3M-57.1%$7M$0-100%$677K-91.2%$7.68M
179.8M+4.8%171.6M-0.5%172.4M+0.7%171.3M+1.2%169.2M+18.5%
-$78.59M-29.6%-$60.63M+24.6%-$80.39M-4.6%-$76.85M+9.5%-$84.87M+0.1%
-$78.09M-30.1%-$60.03M+24.6%-$79.64M-5.0%-$75.85M+9.3%-$83.66M0.0%
-$78.09M-30.1%-$60.03M+24.6%-$79.64M-5.0%-$75.85M+9.3%-$83.66M0.0%
-2,602.9%-1,745pp-857.6%-11,203.1%-10,114pp-1,089.5%
-$78.59M-29.6%-$60.63M+24.6%-$80.39M-4.6%-$76.85M+9.5%-$84.87M+0.1%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Relay Therapeutics, Inc.'s income statement data come from?
Every line is extracted from Relay Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.